The naturally occurring inhibitor of interleukin-1 (IL-1) action, interleukin-1 receptor antagonist protein (IRAP), binds to the type 1 IL-1 receptor but does not initiate IL-1 signal transduction. In this study, we have determined the effects of IL-1b and IRAP overexpression on adult b-cell replication and viability. IL-1b reduced dramatically b-cell replication in adult rat islets both at 5.5 mM (control: 0.2970.04%; IL-1b: 0.0270.02%, Po0.05) and 22.2 mM glucose (control: 0.8470.2%; IL-1b: 0.0570.05%, Po0.05). This effect was completely prevented in islets overexpressing IRAP after adenoviral gene transfer at 5.5 mM (Ad-IL-1Ra+IL-1b: 0.8470.1%, Po0.05) and 22.2 mM glucose (Ad-IL-1Ra+IL-1b: 1.2270.2%, Po0.05). Moreover, overexpression of IRAP increased glucose-stimulated b-cell replication in the absence of IL-1b exposure (Ad-IL-1Ra: 1.5970.5%, Po0.05). b-Cell death (TUNEL technique) was increased in IL-1b-exposed islets but not in Ad-IL-1Ra-infected islets (control: 0.8270.2%; control+IL-1b: 1.7770.2; IRAP: 0.6170.2%; IRAP+IL-1b: 0.8670.1%, Po0.05). Comparable results were obtained by flow cytometry. To determine the effect of IRAP overexpression on b-cell replication in vivo, Ad-IL-1Ra-transduced islets were transplanted into streptozotocin diabetic rats. b-Cell replication was significantly increased in IRAP-overexpressing islet grafts (0.9870.3%, Po0.05) compared to normal pancreas (0.3570.02%), but not in control islet grafts (0.5070.1%). This study shows that in addition to the effects of IL-1b on bcell viability, this cytokine exerts a deleterious action on b-cell replication, which can be prevented by IRAP overexpression, and provides support for the potential use of IRAP as a therapeutic tool. Gene Therapy (2005) 12, 120-128.